GENE ONLINE|News &
Opinion
Blog

2022-04-08| Asia-Pacific

Shionogi and Aichi Prefecture Extends Cooperation on Preventing Drug Abuse

by Joy Lin
Share To

Since 2018, Shionogi and Aichi Prefecture in Japan have been working together to raise awareness for drug abuse prevention and encourage proper use of medicines. Now, the two are extending their collaboration for one more year. 

In 2021, Shionogi and Aichi Prefecture mainly focused on hosting activities such as web seminars. These online events, held in the shadow of the COVID-19 pandemic, sought to inform residents of Aichi Prefecture on how to avoid abusing drugs and use prescription narcotics with discretion. The seminars were sponsored by the Japanese Drug Organization of Appropriate Use and Research (J-DO), an Aichi-based NPO focused on promoting the proper use of drugs, and received support from the Aichi Pharmaceutical Association and the Aichi Society of Hospital Pharmacists. 

 

Drug Abuse in Japan

 

Japan is strict with drug use. Those who take drugs such as cannabis and methamphetamine are subjected to public shaming and stigma, and may also face jail time. Yet, an increasing number of people, especially youths, are taking these drugs, helped by ease of online access. 

Drug abuse covers more than stimulants. Patients may also overdose on prescription narcotics, which have traditionally played an important role in pain management, mainly for cancer pain. 

Home medical care is increasing in the rapidly aging Japanese society, complementing the progress of community-based comprehensive care. 

Shionogi has defined “Improve social productivity and extend healthy lifespans” as one of its key issues to address. Besides promoting proper use of prescription narcotics for cancer pain relief and palliative care, the company intends to implement more initiatives with Aichi Prefecture to prevent the misuse of medicines and help those suffering from chronic pain get relief without abusing prescription drugs. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top